First Patient Dosed in Phase 1/2 Study of TRC253 for Treating Therapy-resistant Prostate Cancer

First Patient Dosed in Phase 1/2 Study of TRC253 for Treating Therapy-resistant Prostate Cancer
The first patient has been dosed in a Phase 1/2a clinical trial that will assess TRACON PharmaceuticalsTRC253 for treating metastatic castration-resistant prostate cancer (mCRPC), a form that has developed resistance against other therapies. TRACON was able to file an Investigational New Drug application with U.S. regulators quickly, "open multiple sites, and dose TRC253 in a Phase 1/2 trial following the establishment of our strategic licensing collaboration with Janssen,” Dr. Charles Theuer, president and CEO of TRACON, said in a
Subscribe or to access all post and page content.